Application of Fuming Tablet Combined with Liraglutide in the Treatment of Diabetic Retinopathy

2021 International Conference on Computer Engineering and Artificial Intelligence (ICCEAI) Pub Date : 2021-08-01 DOI:10.1109/ICCEAI52939.2021.00093

Lijuan Gao, Lingling Wu

{"title":"Application of Fuming Tablet Combined with Liraglutide in the Treatment of Diabetic Retinopathy","authors":"Lijuan Gao, Lingling Wu","doi":"10.1109/ICCEAI52939.2021.00093","DOIUrl":null,"url":null,"abstract":"objective to investigate the application of fuming Tablet combined with Liraglutid in the treatment of diabetic retinopathy and the effect on the level of insulin-like growth factor-1 (IGF-1) and serum vascular endothelial growth factor (VEGF). Methods: 112 cases of diabetic retinopathy were randomly divided into observation group and control group, 56 cases in each group. The control group was treated with liraglutide, and the observation group was treated with fuming tablet and combined treatment with liraglutide. After 4weeks, 3 months and 6 months, the clinical efficacy, visual acuity, macular thickness, VEGF, IGF-1 and the incidence of adverse reactions in 2 groups were statistically compared. Results: The total effective rate of observation group was higher than that of control group (P<0.05). After treatment, the visual acuity, macular thickness, VEGF and IGF-1 levels in the observation group were lower than those in the control group (P <0.05). Conclusion: Fuming tablet combined with liraglutide can improve visual acuity in patients with diabetic retinopathy.","PeriodicalId":331409,"journal":{"name":"2021 International Conference on Computer Engineering and Artificial Intelligence (ICCEAI)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"2021 International Conference on Computer Engineering and Artificial Intelligence (ICCEAI)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1109/ICCEAI52939.2021.00093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

objective to investigate the application of fuming Tablet combined with Liraglutid in the treatment of diabetic retinopathy and the effect on the level of insulin-like growth factor-1 (IGF-1) and serum vascular endothelial growth factor (VEGF). Methods: 112 cases of diabetic retinopathy were randomly divided into observation group and control group, 56 cases in each group. The control group was treated with liraglutide, and the observation group was treated with fuming tablet and combined treatment with liraglutide. After 4weeks, 3 months and 6 months, the clinical efficacy, visual acuity, macular thickness, VEGF, IGF-1 and the incidence of adverse reactions in 2 groups were statistically compared. Results: The total effective rate of observation group was higher than that of control group (P<0.05). After treatment, the visual acuity, macular thickness, VEGF and IGF-1 levels in the observation group were lower than those in the control group (P <0.05). Conclusion: Fuming tablet combined with liraglutide can improve visual acuity in patients with diabetic retinopathy.

查看原文本刊更多论文

烟熏片联合利拉鲁肽治疗糖尿病视网膜病变的应用

目的探讨熏烟片联合利拉鲁tid治疗糖尿病视网膜病变及对胰岛素样生长因子-1 (IGF-1)和血清血管内皮生长因子(VEGF)水平的影响。方法:将112例糖尿病视网膜病变患者随机分为观察组和对照组，每组56例。对照组患者给予利拉鲁肽治疗，观察组患者给予发烟片加利拉鲁肽联合治疗。治疗4周、3个月、6个月后，对两组患者的临床疗效、视力、黄斑厚度、VEGF、IGF-1及不良反应发生率进行统计学比较。结果:观察组患者总有效率高于对照组(P<0.05)。治疗后，观察组患者的视力、黄斑厚度、VEGF、IGF-1水平均低于对照组(P <0.05)。结论:烟熏片联合利拉鲁肽可改善糖尿病视网膜病变患者的视力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

2021 International Conference on Computer Engineering and Artificial Intelligence (ICCEAI)

自引率

0.00%

发文量